Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-2870 Monotherapy and Combination Therapy in Advanced Solid Tumors
NCT06049212Phase 1Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Oct 2023
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of sacituzumab tirumotecan in non-small cell lung cancer (NSCLC) and solid tumor (2 arms), sponsored by Merck & Co. Primary endpoints: Number of Participants Experiencing Dose-Limiting Toxicity, Number of Participants Experiencing ≥1 Adverse Event and 1 more. Started Oct 2023; status: active, not recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
non-small cell lung cancer (NSCLC)solid tumor
Beyond the preview
Go deeper on NCT06049212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06049212.